Citigroup has downgraded 10X Genomics Inc (TXG) to Neutral from Buy, signaling increased caution regarding the company's outlook. The revision, effective December 10, 2025, may reflect concerns about competitive pressures, market conditions, or execution risks that could impact performance.
10X Genomics, headquartered in Pleasanton, California, specializes in life sciences technology, focusing on products that enable researchers to interrogate and understand biology. The firm, which went public on September 12, 2019, currently has a market capitalization of $2.1 billion and employs 1,306 full-time staff. Its integrated solutions include instruments, consumables, and software for single-cell and spatial biology systems.
As of November 20, 2025, the company's stock is priced at $15.56. Analysts have mixed views on 10X Genomics, with a consensus rating of Buy based on 5 Strong Buy, 5 Buy, 13 Hold, and no Sell or Strong Sell ratings. The upcoming earnings report is scheduled for August 5, 2026, with an estimated EPS of -$0.24 and revenue of $151.1 million.
Analyst ratings and price targets provide insights based on research and financial models, but they are not definitive predictors of future performance. Investors should consider multiple factors, including company fundamentals and industry trends, when making decisions. It's also important to note that analyst ratings can evolve as new information emerges.